WO2012125732A8 - Substituted imadazapyrinidin-5(6h)-ones as allosteric modulators of mglur5 receptors - Google Patents

Substituted imadazapyrinidin-5(6h)-ones as allosteric modulators of mglur5 receptors Download PDF

Info

Publication number
WO2012125732A8
WO2012125732A8 PCT/US2012/029085 US2012029085W WO2012125732A8 WO 2012125732 A8 WO2012125732 A8 WO 2012125732A8 US 2012029085 W US2012029085 W US 2012029085W WO 2012125732 A8 WO2012125732 A8 WO 2012125732A8
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
allosteric modulators
imadazapyrinidin
ones
substituted
Prior art date
Application number
PCT/US2012/029085
Other languages
French (fr)
Other versions
WO2012125732A1 (en
Inventor
P. Jeffrey Conn
Craig W. LINSLEY
Shaun R. Stauffer
Jose Manuel Bartolome-Nebreda
Gregor James Macdonald
Susana Conde-Ceide
Carrie K. Jones
Maria Luz Martin-Martin
Han Min Tong
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Priority to EP12757940.7A priority Critical patent/EP2685825A4/en
Priority to CA2830220A priority patent/CA2830220A1/en
Priority to JP2013558139A priority patent/JP2014508172A/en
Priority to AU2012229983A priority patent/AU2012229983A1/en
Publication of WO2012125732A1 publication Critical patent/WO2012125732A1/en
Publication of WO2012125732A8 publication Critical patent/WO2012125732A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

In one aspect, the invention relates to imidazopyrimidin-5(6H)-one analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
PCT/US2012/029085 2011-03-15 2012-03-14 Substituted imadazapyrinidin-5(6h)-ones as allosteric modulators of mglur5 receptors WO2012125732A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP12757940.7A EP2685825A4 (en) 2011-03-15 2012-03-14 Substituted imadazopyrimidin-5(6h)-ones as allosteric modulators of mglur5 receptors
CA2830220A CA2830220A1 (en) 2011-03-15 2012-03-14 Substituted imidazopyrimidin-5(6h)-ones as allosteric modulators of mglur5 receptors
JP2013558139A JP2014508172A (en) 2011-03-15 2012-03-14 Substituted imidazopyrimidin-5 (6H) -ones as allosteric modulators of the MGLUR5 receptor
AU2012229983A AU2012229983A1 (en) 2011-03-15 2012-03-14 Substituted imadazapyrinidin-5(6H)-ones as allosteric modulators of mGluR5 receptors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161452921P 2011-03-15 2011-03-15
US61/452,921 2011-03-15

Publications (2)

Publication Number Publication Date
WO2012125732A1 WO2012125732A1 (en) 2012-09-20
WO2012125732A8 true WO2012125732A8 (en) 2013-10-17

Family

ID=46831091

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/029085 WO2012125732A1 (en) 2011-03-15 2012-03-14 Substituted imadazapyrinidin-5(6h)-ones as allosteric modulators of mglur5 receptors

Country Status (5)

Country Link
EP (1) EP2685825A4 (en)
JP (1) JP2014508172A (en)
AU (1) AU2012229983A1 (en)
CA (1) CA2830220A1 (en)
WO (1) WO2012125732A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013544891A (en) 2010-12-08 2013-12-19 ヴァンダービルト ユニバーシティー Bicyclic pyrazole compounds as allosteric modulators of the mGLUR5 receptor
US8865725B2 (en) * 2011-03-15 2014-10-21 Vanderbilt University Substituted imidazopyrimidin-5(6H)-ones as allosteric modulators of MGLUR5 receptors
EP2864331B1 (en) * 2012-06-21 2017-08-09 Bristol-Myers Squibb Company Positive allosteric modulators of mglur2
TWI713497B (en) * 2015-02-26 2020-12-21 南韓商愛思開生物製藥股份有限公司 Imidazopyrimidine and imidazotriazine derivative, and pharmaceutical composition comprising the same
AU2020370958A1 (en) * 2019-10-21 2022-06-09 Sk Biopharmaceuticals Co., Ltd. Use of imidazopyrimidine or imidazotriazine compounds for prevention, alleviation, or treatment of cognitive disorders, or for improving cognitive function
WO2023064223A1 (en) 2021-10-11 2023-04-20 Gossamer Bio Services, Inc. Tri-substituted pyridines

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8334210D0 (en) * 1983-12-22 1984-02-01 Roussel Lab Ltd Imidazo(1 2-c)pyrimidines
JPH01203366A (en) * 1988-02-10 1989-08-16 Mitsui Petrochem Ind Ltd N-substituted imidazole derivative
WO2007034282A2 (en) * 2005-09-19 2007-03-29 Pfizer Products Inc. Diaryl-imidazole compounds condensed with a heterocycle as c3a receptor antagonists
PL2054416T3 (en) * 2006-08-04 2011-05-31 Merz Pharma Gmbh & Co Kgaa Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine
US20080146523A1 (en) * 2006-12-18 2008-06-19 Guido Galley Imidazole derivatives
GB0704230D0 (en) * 2007-03-05 2007-04-11 Novartis Ag Organic compounds
US8034806B2 (en) * 2007-11-02 2011-10-11 Vanderbilt University Bicyclic mGluR5 positive allosteric modulators and methods of making and using same
WO2012083224A1 (en) * 2010-12-17 2012-06-21 Vanderbilt University Bicyclic triazole and pyrazole lactams as allosteric modulators of mglur5 receptors

Also Published As

Publication number Publication date
EP2685825A1 (en) 2014-01-22
EP2685825A4 (en) 2014-09-10
JP2014508172A (en) 2014-04-03
CA2830220A1 (en) 2012-09-20
WO2012125732A1 (en) 2012-09-20
AU2012229983A1 (en) 2013-10-03

Similar Documents

Publication Publication Date Title
WO2012118563A3 (en) 6-alkyl-n-(pyridin-2-yl)-4-aryloxypicolinamide analogs as mglur5 negative allosteric modulators and methods of making and using the same
MX2009013169A (en) Benzamide mglur5 positive allosteric modulators and methods of making and using same.
WO2015200682A8 (en) Substituted 4-alkoxypicolinamide analogs ds mglur5 negative allosteric modulators
EP2575461A4 (en) Substituted-6-methylnicotinamides as mglur5 positive allosteric modulators
WO2012125732A8 (en) Substituted imadazapyrinidin-5(6h)-ones as allosteric modulators of mglur5 receptors
CO2018004800A2 (en) Muscarinic 4 receptor antagonists and methods of use.
WO2014055928A3 (en) Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
WO2013170072A3 (en) Compounds for the treatment of neurological disorders
EA201190302A1 (en) 7-aryl-1,2,4-triazole [4,3-a] pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
WO2014055934A3 (en) Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
PH12015502685A1 (en) 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
EA201591204A3 (en) NEW CHIRAL N-ACYL-5,6,7, (8-SUBSTITUTED) -TETRAHYDRO- [1,2,4] TRIAZOLO [4,3-A] PIRASINS AS SELECTIVE ANTAGONISTS OF NK-3 RECEPTOR, PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL COMPOSITION NK-3, PHARMACEUTICAL COMPOSITION ANTAGONISTS, PHARMACEUTICAL COMPOSITION NK-3 NON-MEDIATED DISORDERS NK-3 RECEPTORS AND THEIR CHIRAL SYNTHESIS
MY153912A (en) 1, 2, 4,-triazolo[4,3-a[pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
MX2011005242A (en) Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors.
JO2907B1 (en) 1,2,4TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
MX2012013031A (en) Heterocyclic sulfone mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction.
EA200901160A1 (en) DERIVATIVES 3-CYANO-4- (4-TETRAGIDROPIRANPHENYL) PYRIDIN-2-IT
IN2014CN00961A (en)
ES2721018T3 (en) N-Acyl- (3-substituted) - (8-methyl) -5,6-dihydro- [1,2,4] triazolo [4,3-a] pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in disorders mediated by the NK-3 receptor
MX353209B (en) D2 ANTAGONISTS, METHODS OF SYNTHESIS and METHODS OF USE.
WO2013042135A8 (en) Heteroaryl compounds as 5-ht4 receptor ligands
WO2011112825A3 (en) Heterocyclyl-azabicyclo[3.2.1]octane analogs as selective m1 agonists and methods of making and using same
MX339858B (en) Novel compounds as histamine h3 receptor ligands.
CO6541592A2 (en) BICYCLE TIAZOLS AS MGLUR5 ALLOSTERIC RECEIVER MODULATORS
IN2012DN03322A (en)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12757940

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase in:

Ref document number: 2830220

Country of ref document: CA

Ref document number: 2013558139

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase in:

Ref country code: DE

ENP Entry into the national phase in:

Ref document number: 2012229983

Country of ref document: AU

Date of ref document: 20120314

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2012757940

Country of ref document: EP